Age-standardized death from lymphomas and multiple myeloma per 100,000 inhabitants in 2004 Unlike some other lymphomas, whose number of new cases per year increases with age,<unk>  has a bimodal curve for the number of cases; that is, it occurs most frequently in two separate age groups, the first being young adulthood (age 15–35) and the second being in those over 55 years old although these peaks may vary slightly with nationality. Overall, it is more common in males, except for the nodular sclerosis variant, which is slightly more common in females. The annual number of cases of<unk>  is 2.7 per 100,000 per persons per year, and the disease accounts for slightly less than 1% of all cancers worldwide. In 2010, globally it resulted in about 18,000 deaths down from 19,000 in 1990. In 2012, there were an estimated 65,950 cases and 25,469 deaths from<unk>  worldwide, with 28,852 and 37,098 cases occurring in developed and developing countries, respectively. However, the age-standardized rates were higher in developed regions, with the greatest rates in the Americas (1.5 per 100,000), East Mediterranean Region (1.5 per 100,000), and Europe (2.0 per 100,000). The East Mediterranean Region also has the highest age-standardized mortality rate of 1.0 per 100,000, which is mainly attributed to lifestyle and environmental risk factors associated with transitional economies such as smoking, obesity, physical inactivity, and reproductive behaviors, as well as availability of diagnostic practices and awareness of the disease. The number of cases of<unk>  is increased in people with HIV infection. In contrast to many other lymphomas associated with HIV infection it occurs most commonly in people with higher CD4 T cell counts. Canada<unk>  accounts for 0.6% of all male cancer cases, and 0.4% of all female cancer cases in Canada. In 2017, approximately 990 Canadians will be diagnosed with<unk> , and 140 will die of the disease. UK<unk>  accounts for less than 1% of all cancer cases and deaths in the UK. Around 1,800 people were diagnosed with the disease in 2011, and around 330 people died in 2012. United States In 2016, there were 8,389 new cases and 1,000 mortalities attributed to<unk> , a decrease from the 8,625 new cases and 1,120 mortalities in 2015. As of January 1, 2016, the 5-year limited duration prevalence of<unk>  was 37,513 representing 0.71% of all diagnosed cancers in the U.S.
Hodgkin lymphoma
AIDS-related lymphoma
Burkitt lymphoma
B-cell lymphoma
Aggressive lymphoma
Primary effusion lymphoma
Thymoma with immunodeficiency
Thymic carcinoma